Eli Lilly Receives High Rating from Guru Growth Model

Eli Lilly’s stock is rated 88% by a leading growth strategy, highlighting its strong fundamentals. This high score indicates significant investor interest and the potential for future growth.

Date: 09-03-2025

AI Rating: 7

Earnings Per Share (EPS): The report does not provide specific EPS data.
Revenue Growth: Revenue growth specifics are not mentioned in the report.
Net Income: There is no mention of net income figures.
Profit Margins: Specific profit margins such as gross, operating, or net are not detailed.
Free Cash Flow (FCF): The report does not discuss free cash flow.
Return on Equity (ROE): Return on Equity is not explicitly mentioned, but other financial performance indicators suggest a positive outlook.

In summary, Eli Lilly and Co. (LLY) is highlighted as a large-cap growth stock within the Biotechnology & Drugs industry with an impressive 88% rating according to the growth investor strategy developed by Partha Mohanram. The report indicates that a rating above 80% reflects a strong interest in the stock, with scores above 90% suggesting exceptional potential. The positive aspects identified in the criteria such as the book-to-market ratio, return on assets, and various cash flow metrics show the underlying strength of the company's fundamentals.
However, one area where LLY does not pass is in Research and Development to Assets, suggesting potential concerns about investment in innovation, which is critical in the biotech sector. While this could signal a potential risk, the overall high rating and passing marks in various other categories may outweigh this concern for many investors. Investors may perceive the stock as a favorable option given its current positive outlook based on the growth strategy reviewed in this analysis.

Stocks: LLY